$AMRX
Amneal Pharmaceuticals, Inc.

2021 Q1 Form 10-Q Financial Statement

#000172312821000023 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $493.1M $498.5M
YoY Change -1.09% 11.75%
Cost Of Revenue $301.5M $313.6M
YoY Change -3.84% 1.24%
Gross Profit $191.6M $183.5M
YoY Change 4.39% 120.87%
Gross Profit Margin 38.85% 36.81%
Selling, General & Admin $90.73M $77.98M
YoY Change 16.35% -7.65%
% of Gross Profit 47.36% 42.49%
Research & Development $48.18M $36.38M
YoY Change 32.44% -32.45%
% of Gross Profit 25.15% 19.83%
Depreciation & Amortization $55.50M $58.10M
YoY Change -4.48% 18.81%
% of Gross Profit 28.97% 31.66%
Operating Expenses $138.9M $114.4M
YoY Change 21.47% -17.31%
Operating Profit $45.91M $57.79M
YoY Change -20.56% -161.25%
Interest Expense -$33.89M -$39.90M
YoY Change -15.07% -7.81%
% of Operating Profit -73.81% -69.04%
Other Income/Expense, Net -$31.00M -$44.45M
YoY Change -30.25% 14.5%
Pretax Income $14.90M $13.34M
YoY Change 11.69% -110.02%
Income Tax $400.0K -$108.0M
% Of Pretax Income 2.68% -809.35%
Net Earnings $12.75M $120.4M
YoY Change -89.41% -351.52%
Net Earnings / Revenue 2.59% 24.16%
Basic Earnings Per Share $0.05 $0.78
Diluted Earnings Per Share $0.04 $0.78
COMMON SHARES
Basic Shares Outstanding 148.0M shares 147.2M shares
Diluted Shares Outstanding 151.2M shares 148.0M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $452.1M $405.2M
YoY Change 11.57% 534.12%
Cash & Equivalents $452.1M $405.2M
Short-Term Investments
Other Short-Term Assets $78.80M $40.90M
YoY Change 92.67% -64.25%
Inventory $497.0M $438.0M
Prepaid Expenses
Receivables $530.6M $722.7M
Other Receivables $1.100M $16.36M
Total Short-Term Assets $1.560B $1.774B
YoY Change -12.07% 39.89%
LONG-TERM ASSETS
Property, Plant & Equipment $471.2M $467.6M
YoY Change 0.77% -9.11%
Goodwill $522.8M $514.7M
YoY Change 1.56% 22.08%
Intangibles $1.263B $1.475B
YoY Change -14.39% -7.29%
Long-Term Investments
YoY Change
Other Assets $19.56M $26.46M
YoY Change -26.06% -57.62%
Total Long-Term Assets $2.400B $2.617B
YoY Change -8.28% -16.03%
TOTAL ASSETS
Total Short-Term Assets $1.560B $1.774B
Total Long-Term Assets $2.400B $2.617B
Total Assets $3.960B $4.391B
YoY Change -9.81% 0.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $574.3M $606.9M
YoY Change -5.37% 8.61%
Accrued Expenses $9.500M $16.20M
YoY Change -41.36% 5.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $300.0M
YoY Change -100.0%
Long-Term Debt Due $29.82M $29.74M
YoY Change 0.27% 32.16%
Total Short-Term Liabilities $636.8M $965.1M
YoY Change -34.02% 60.97%
LONG-TERM LIABILITIES
Long-Term Debt $2.728B $2.772B
YoY Change -1.58% 5.59%
Other Long-Term Liabilities $63.79M $80.85M
YoY Change -21.1% 114.31%
Total Long-Term Liabilities $2.944B $3.010B
YoY Change -2.2% 0.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $636.8M $965.1M
Total Long-Term Liabilities $2.944B $3.010B
Total Liabilities $3.580B $3.975B
YoY Change -9.92% 10.88%
SHAREHOLDERS EQUITY
Retained Earnings -$280.1M -$262.8M
YoY Change 6.58% 311.65%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $323.0M $318.4M
YoY Change
Total Liabilities & Shareholders Equity $3.960B $4.391B
YoY Change -9.81% 0.14%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $12.75M $120.4M
YoY Change -89.41% -351.52%
Depreciation, Depletion And Amortization $55.50M $58.10M
YoY Change -4.48% 18.81%
Cash From Operating Activities $148.1M $49.03M
YoY Change 202.14% -145.22%
INVESTING ACTIVITIES
Capital Expenditures $11.78M $7.367M
YoY Change 59.85% -59.04%
Acquisitions $0.00 $253.6M
YoY Change -100.0%
Other Investing Activities $0.00 -$253.6M
YoY Change -100.0% 7145.71%
Cash From Investing Activities -$12.69M -$262.0M
YoY Change -95.16% 1120.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$26.15M $468.0M
YoY Change -105.59% -2240.41%
NET CHANGE
Cash From Operating Activities $148.1M $49.03M
Cash From Investing Activities -$12.69M -$262.0M
Cash From Financing Activities -$26.15M $468.0M
Net Change In Cash $108.7M $254.1M
YoY Change -57.22% -267.13%
FREE CASH FLOW
Cash From Operating Activities $148.1M $49.03M
Capital Expenditures $11.78M $7.367M
Free Cash Flow $136.4M $41.66M
YoY Change 227.31% -132.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
301543000 USD
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001723128
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38485
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Amneal Pharmaceuticals, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0546926
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
400 Crossing Boulevard,
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bridgewater
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08807
CY2021Q1 dei City Area Code
CityAreaCode
908
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
947-3120
CY2021Q1 dei Security12b Title
Security12bTitle
Class A Common Stock, par value $0.01 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
AMRX
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
498533000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
313578000 USD
CY2021Q1 amrx Cost Of Goods And Services Sold Impairment Charges
CostOfGoodsAndServicesSoldImpairmentCharges
0 USD
CY2020Q1 amrx Cost Of Goods And Services Sold Impairment Charges
CostOfGoodsAndServicesSoldImpairmentCharges
1456000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
191562000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
183499000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90726000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
77976000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48182000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36379000 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
960000 USD
CY2021Q1 us-gaap Royalty Expense
RoyaltyExpense
3582000 USD
CY2020Q1 us-gaap Royalty Expense
RoyaltyExpense
1270000 USD
CY2021Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2802000 USD
CY2020Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2575000 USD
CY2021Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2020Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-4500000 USD
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
363000 USD
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
2048000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
45907000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
57791000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33885000 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-39899000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2088000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5181000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
794000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
633000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31003000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-44447000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14904000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13344000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
359000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-108173000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
121517000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7839000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6450000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
115067000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148013000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147180000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151220000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147956000 shares
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
121517000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7839000 USD
CY2020Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6450000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
115067000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6366000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-5135000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20772000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-62658000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
7302000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-34456000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
7104000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-33337000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13810000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
81730000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452097000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
341378000 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3717000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
5743000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
530600000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
638895000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
497008000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
490649000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75137000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73467000 USD
CY2021Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1102000 USD
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1407000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1559661000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1551539000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
471165000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
477754000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
522758000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
522814000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1262954000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1304626000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19561000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22344000 USD
CY2021Q1 us-gaap Assets
Assets
3960070000 USD
CY2020Q4 us-gaap Assets
Assets
4006033000 USD
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
574322000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
611867000 USD
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
29817000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
44228000 USD
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
20100000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7561000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
636779000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
676902000 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2728212000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2735264000 USD
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
36828000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
36440000 USD
CY2021Q1 us-gaap Due To Affiliate Noncurrent
DueToAffiliateNoncurrent
2061000 USD
CY2020Q4 us-gaap Due To Affiliate Noncurrent
DueToAffiliateNoncurrent
1584000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
63789000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
83365000 USD
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2943504000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2972395000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
13079000 USD
CY2020Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
11804000 USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
634484000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
628413000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280115000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-286821000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34361000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-41318000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
323015000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
303271000 USD
CY2021Q1 us-gaap Minority Interest
MinorityInterest
43693000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
41661000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
366708000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
344932000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3960070000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4006033000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
14545000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
121517000 USD
CY2021Q1 amrx Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
55549000 USD
CY2020Q1 amrx Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs
DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
58083000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1970000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-5514000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2183000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2004000 USD
CY2021Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2416000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5330000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4539000 USD
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
16021000 USD
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
15200000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1431000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1266000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-108385000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
60893000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20283000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2778000 USD
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 USD
CY2020Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
110069000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-602000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26383000 USD
CY2021Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-301000 USD
CY2020Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-76000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37226000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
34839000 USD
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
3260000 USD
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
3695000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
148128000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
49026000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11776000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7367000 USD
CY2021Q1 amrx Payments To Acquire Property Plant And Equipment Deposits
PaymentsToAcquirePropertyPlantAndEquipmentDeposits
917000 USD
CY2020Q1 amrx Payments To Acquire Property Plant And Equipment Deposits
PaymentsToAcquirePropertyPlantAndEquipmentDeposits
0 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1050000 USD
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2020Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
253625000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12693000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-262042000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
0 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
180000000 USD
CY2021Q1 amrx Repayments Of Long Term Debt And Financing Lease Obligations
RepaymentsOfLongTermDebtAndFinancingLeaseObligations
23630000 USD
CY2020Q1 amrx Repayments Of Long Term Debt And Financing Lease Obligations
RepaymentsOfLongTermDebtAndFinancingLeaseObligations
7158000 USD
CY2021Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2020Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
300000000 USD
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2020Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4102000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
676000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2102000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
503000 USD
CY2021Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1000000 USD
CY2020Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26149000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
467979000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-593000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-860000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
108693000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
254103000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
347121000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152822000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455814000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
406925000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452097000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
405238000 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3717000 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1687000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
455814000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
406925000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
29917000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
35386000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
733000 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3430000 USD
CY2021Q1 amrx Tax Distribution To Non Controlling Interest
TaxDistributionToNonControllingInterest
9757000 USD
CY2020Q1 amrx Tax Distribution To Non Controlling Interest
TaxDistributionToNonControllingInterest
0 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
344932000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4539000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2020Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
11804000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
12749000 USD
CY2021Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1796000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6366000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5330000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
676000 USD
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2149000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20772000 USD
CY2021Q1 amrx Temporary Equity Tax Distribution
TemporaryEquityTaxDistribution
521000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
366708000 USD
CY2021Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
13079000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
346788000 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
120429000 USD
CY2020Q1 us-gaap Temporary Equity Net Income
TemporaryEquityNetIncome
1088000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-5135000 USD
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-510000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-62658000 USD
CY2020Q1 amrx Temporary Equity Increase From Business Combination
TemporaryEquityIncreaseFromBusinessCombination
11475000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
403458000 USD
CY2020Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
12563000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of </span></div>expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period balances related to (i) financing lease right-of-use assets of $10 million formerly included in other assets, (ii) current portion of financing lease liabilities of $2 million formerly included in accounts payable and accrued expenses, and (iii) long-term lease liabilities of $2 million formerly included in other long-term liabilities as of December 31, 2020 have been reclassified to their respective balance sheet captions to conform to the current period presentation in the consolidated balance sheets.</span></div>
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
10000000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2000000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2000000 USD
CY2020Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
525303000 USD
CY2020Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
122521000 USD
CY2020Q1 amrx Business Acquisition Pro Forma Net Income Loss Attributable To Common Shareholders
BusinessAcquisitionProFormaNetIncomeLossAttributableToCommonShareholders
115388000 USD
CY2021Q1 amrx Concentration Risk Number Of Largest Customers
ConcentrationRiskNumberOfLargestCustomers
3 customer
CY2020Q1 amrx Concentration Risk Number Of Largest Customers
ConcentrationRiskNumberOfLargestCustomers
3 customer
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
498533000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6706000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
115067000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148013000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147180000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151220000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147956000 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-8.106
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.024
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-108000000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-110000000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
423000000 USD
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
345000000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-110000000 USD
CY2020Q3 amrx Income Taxes Receivable Net Operating Loss Cares Act Amount Refunded
IncomeTaxesReceivableNetOperatingLossCARESActAmountRefunded
106000000 USD
CY2020Q3 amrx Income Taxes Receivable Net Operating Loss Cares Act
IncomeTaxesReceivableNetOperatingLossCARESAct
110000000 USD
CY2020Q3 amrx Income Taxes Receivable Net Operating Loss Cares Act Interest
IncomeTaxesReceivableNetOperatingLossCARESActInterest
4000000 USD
CY2021Q1 amrx Income Taxes Receivable Net Operating Loss Cares Act Amount Refunded
IncomeTaxesReceivableNetOperatingLossCARESActAmountRefunded
2000000 USD
CY2018Q2 amrx Percentage Of Tax Benefits Under Tax Receivable Agreement
PercentageOfTaxBenefitsUnderTaxReceivableAgreement
0.85
CY2021Q1 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206000000 USD
CY2020Q4 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206000000 USD
CY2021Q1 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206000000 USD
CY2020Q4 amrx Liabilities Under Tax Receivable Agreement Noncurrent
LiabilitiesUnderTaxReceivableAgreementNoncurrent
206000000 USD
CY2021Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1072138000 USD
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1291785000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1444000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1396000 USD
CY2021Q1 amrx Contract Charge Backs And Sales Volume Allowances Current
ContractChargeBacksAndSalesVolumeAllowancesCurrent
517758000 USD
CY2020Q4 amrx Contract Charge Backs And Sales Volume Allowances Current
ContractChargeBacksAndSalesVolumeAllowancesCurrent
628804000 USD
CY2021Q1 amrx Cash Discount Allowances Current
CashDiscountAllowancesCurrent
22336000 USD
CY2020Q4 amrx Cash Discount Allowances Current
CashDiscountAllowancesCurrent
22690000 USD
CY2021Q1 amrx Allowance For Accounts Receivable Current
AllowanceForAccountsReceivableCurrent
541538000 USD
CY2020Q4 amrx Allowance For Accounts Receivable Current
AllowanceForAccountsReceivableCurrent
652890000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
530600000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
638895000 USD
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
205874000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
209180000 USD
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
51633000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
40937000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
239501000 USD
CY2021Q1 us-gaap Interest Rate Cash Flow Hedge Liability At Fair Value
InterestRateCashFlowHedgeLiabilityAtFairValue
33131000 USD
CY2021Q1 amrx Deferred Compensation Plan Liabilities Fair Value Disclosures
DeferredCompensationPlanLiabilitiesFairValueDisclosures
14500000 USD
CY2020Q4 us-gaap Interest Rate Cash Flow Hedge Liability At Fair Value
InterestRateCashFlowHedgeLiabilityAtFairValue
53903000 USD
CY2020Q4 amrx Deferred Compensation Plan Liabilities Fair Value Disclosures
DeferredCompensationPlanLiabilitiesFairValueDisclosures
14007000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
240532000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
497008000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
490649000 USD
CY2021Q1 us-gaap Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax
AociLossCashFlowHedgeCumulativeGainLossAfterTax
-33000000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
522814000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
419504000 USD
CY2021Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
103679000 USD
CY2021Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-56000 USD
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-369000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
522758000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
522814000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1283045000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
399486000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
883559000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1286896000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
361665000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
925231000 USD
CY2021Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
379395000 USD
CY2021Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
379395000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
379395000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
379395000 USD
CY2021Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
1662440000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
399486000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1262954000 USD
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
1666291000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
361665000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1304626000 USD
CY2021Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2021Q1 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
131000000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41672000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
42576000 USD
CY2021Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
379000000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
125091000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
155162000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
143395000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
136910000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
97937000 USD
CY2021Q1 amrx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
225064000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
883559000 USD
CY2014Q4 amrx Number Of Sales Representatives
NumberOfSalesRepresentatives
1 representative
CY2020Q4 amrx Loss Contingency Pending Claims Including Third Parties Number
LossContingencyPendingClaimsIncludingThirdPartiesNumber
880 case
CY2020Q4 amrx Loss Contingency Number Of Cases
LossContingencyNumberOfCases
120 case
CY2020Q4 amrx Loss Contingency Number Of States With Cases
LossContingencyNumberOfStatesWithCases
11 state
CY2017Q2 amrx Number Of Former Officers Alleging Violations
NumberOfFormerOfficersAllegingViolations
4 officer
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2021Q1 amrx Number Of Product Families
NumberOfProductFamilies
250 product
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493105000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
301543000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
191562000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90726000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48182000 USD
CY2021Q1 us-gaap Royalty Expense
RoyaltyExpense
3582000 USD
CY2021Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2802000 USD
CY2021Q1 us-gaap Restructuring Charges
RestructuringCharges
363000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
45907000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
498533000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
313578000 USD
CY2020Q1 amrx Cost Of Goods And Services Sold Impairment Charges
CostOfGoodsAndServicesSoldImpairmentCharges
1456000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
183499000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
77976000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36379000 USD
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
960000 USD
CY2020Q1 us-gaap Royalty Expense
RoyaltyExpense
1270000 USD
CY2020Q1 amrx Business Combination Acquisition Related Costs Transaction Related And Integration Expense
BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense
2575000 USD
CY2020Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-4500000 USD
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
2048000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
57791000 USD
CY2021Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
9000000 USD
CY2020Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
0 USD
CY2021Q1 amrx Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders
RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
500000 USD
CY2020Q1 amrx Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders
RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
0 USD
CY2020 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-41203000 USD
CY2020 amrx Changes In Reallocation Of Ownership Interests
ChangesInReallocationOfOwnershipInterests
-47000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
7104000 USD
CY2021Q1 amrx Changes In Reallocation Of Ownership Interests
ChangesInReallocationOfOwnershipInterests
-147000 USD

Files In Submission

Name View Source Status
0001723128-21-000023-index-headers.html Edgar Link pending
0001723128-21-000023-index.html Edgar Link pending
0001723128-21-000023.txt Edgar Link pending
0001723128-21-000023-xbrl.zip Edgar Link pending
amrx-20210331.htm Edgar Link pending
amrx-20210331.xsd Edgar Link pending
amrx-2021033110xqexx101.htm Edgar Link pending
amrx-2021033110xqexx102.htm Edgar Link pending
amrx-2021033110xqexx31.htm Edgar Link pending
amrx-2021033110xqexx311.htm Edgar Link pending
amrx-2021033110xqexx312.htm Edgar Link pending
amrx-2021033110xqexx313.htm Edgar Link pending
amrx-2021033110xqexx321.htm Edgar Link pending
amrx-2021033110xqexx322.htm Edgar Link pending
amrx-2021033110xqexx323.htm Edgar Link pending
amrx-20210331_cal.xml Edgar Link unprocessable
amrx-20210331_def.xml Edgar Link unprocessable
amrx-20210331_htm.xml Edgar Link completed
amrx-20210331_lab.xml Edgar Link unprocessable
amrx-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending